Literature DB >> 14711145

Comparing therapy costs for physician treatment of warts.

Robert J Clemons1, Annette Clemons-Miller, Sandra Marchese Johnson, Susan K Williamson, Thomas D Horn.   

Abstract

To compare the cost of several common modalities used to treat non-genital warts in immunocompetent patients, we identified studies published in English using standard search strategies and evaluated the literature for the following common non-genital wart therapies: cryotherapy with liquid nitrogen, carbon dioxide and pulsed-dye laser therapy, topical squaric acid, intralesional bleomycin, intralesional interferon alpha injections, and intralesional immunotherapy with Candida antigens. Standard treatment algorithms, compiled by dermatologists experienced in the treatment of patients with moderate wart burdens, were utilized for cost-comparison analyses. Based on the cost analysis model, the least expensive treatment option for non-genital warts were carbon dioxide laser therapy (157 dollars) and Candida antigen injections (190 dollars). The other treatment modalities examined ranged from 495 dollars (bleomycin) to 1227 dollars (interferon alpha). Although treatment with the carbon dioxide laser therapy is the least expensive, pain and post-procedure complications limit the use of this modality.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14711145

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  2 in total

Review 1.  [Laser treatment of warts].

Authors:  H M Ockenfels; S Hammes
Journal:  Hautarzt       Date:  2008-02       Impact factor: 0.751

2.  Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans.

Authors:  Sanne P Smeekens; Aylwin Ng; Vinod Kumar; Melissa D Johnson; Theo S Plantinga; Cleo van Diemen; Peer Arts; Eugène T P Verwiel; Mark S Gresnigt; Karin Fransen; Suzanne van Sommeren; Marije Oosting; Shih-Chin Cheng; Leo A B Joosten; Alexander Hoischen; Bart-Jan Kullberg; William K Scott; John R Perfect; Jos W M van der Meer; Cisca Wijmenga; Mihai G Netea; Ramnik J Xavier
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.